VolitionRx (NYSE-A:VNRX) has outlined its plans to advance its veterinary diagnostics platform after a successful 2023.
Among the notable achievements in the past year, Volition successfully launched the Nu.Q Vet Cancer Test in significant markets through various licensing, supply, and distribution agreements.
The company also secured additional agreements to broaden global access to the Nu.Q Vet Cancer Test in 2024.
Additionally, Volition focused on a market access program for Nu.Q NETs, collaborating with global Centers of Excellence to showcase its clinical utility.
In terms of regulatory progress, Volition completed the Q-Sub process with the US Food and Drug Administration, establishing a clear regulatory pathway for Nu.Q NETs. The company also announced a breakthrough early cancer detection method and continued to strengthen its strategic patent portfolio.
Cameron Reynolds, CEO of Volition, highlighted the company's commitment to saving lives and improving outcomes for people and animals worldwide through its novel epigenetics platform. "We believe we made great progress in our mission throughout 2023 and have in place compelling plans to move forward in 2024."
Volition is actively developing user-friendly, cost-effective blood tests to aid in the diagnosis and monitoring of various life-altering diseases in both humans and animals.